請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20167
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭斯傑(Sy-Jye Guo) | |
dc.contributor.author | "Yu, Wen-Li" | en |
dc.contributor.author | 喻文莉 | zh_TW |
dc.date.accessioned | 2021-06-08T02:41:21Z | - |
dc.date.copyright | 2018-03-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-02-12 | |
dc.identifier.citation | 1. Baram, M.: Biotechnological Research on the Most Dangerous Pathogens: Challenges for Risk Governance and Safety Management. Safety Sci, 47 (6), 890-898 (2009).
2. Chang, L. M.: High-Tech Facility Engineering in NT Era. CECI Engineering Technology, 74, 22-37 (2007). 3. Gaudioso, J., Gribble, L. A., and Salerno, R. M.: Biosecurity: Progress and Challenges. J Lab Autom, 14 (3), 141-147 (2009). 4. Kubica, G. P.: Your Tuberculosis Laboratory: Are You Really Safe from Infection? Clin Microbiol News, 12 (11), 85-87 (1990). 5. Löfstedt, R.: Good and Bad Examples of Siting and Building Biosafety Level 4 Laboratories: a Study of Winnipeg, Galveston and Etobicoke. J Hazard Mater, 93 (1), 47-66 (2002). 6. Mourya, D. T., Yadav, P. D., Majumdar, T. D., Chauhan, D. S., and Katoch, V. M.: Establishment of Biosafety Level-3 (BSL-3) Laboratory: Important Criteria To Consider while Designing, Constructing, Commissioning and Operating the Facility in Indian Setting. Indian J Med Res, 140 (2), 171 (2014). 7. Nordmann, B. D.: Issues in Biosecurity and Biosafety. Int J Antimicrob Ag, 36, S66-S69 (2010). 8. Nisii, C., Castilletti, C., Raoul, H., Hewson, R., Brown, D., Gopal, R., Eickmann, M., Gunther, S., Mirazimi, A., Koivula, T., Feldmann, H., Caro, A. D., Capobianchi, M. R., and Ippolito, G.: Biosafety Level-4 Laboratories in Europe: Opportunities for Public Health, Diagnostics, and Research. PLoS Pathogens, 9 (1), e1003105 (2013). 9. Sarafis, P., Stavrakakis, P., Chalaris, M., Stamataki, P., Zyga, S., and Saroglou, G.: Emerging Infectious Diseases. J Environ Prot Ecol, 11 (3), 917-929 (2010). 10. Sewell, D. L.: Laboratory-acquired Infections: Are Microbiologists at Risk? Clin Microbiol News, 28 (1), 1-6(2006). 11. Tubito, P. J., and Latham, T. J.: Contamination Control Facilities for the Biotechnology Industry. In: Cleanroom Design (Ed. W. Whyte). Wiley, Chichester, UK, 1999, 123–139. 12. Uysal, F., and Baylan, A.: Sterilization of Medical Wastes in Edirne, Turkey. J Environ Prot Ecol, 13 (2), 585-592 (2012). 13. Wagner, J. T.: Demystifying Biological Safety Cabinets–Getting the Most Out of the Primary Engineering Controls Used in Microbiology Laboratories. Clin Microbiol News, 29 (14), 105-111 (2007). 14. Yu, W. L., and Guo, S. J.: Architecture of Biosafety and Biosecurity Design: Lesson Learned From Two Biologics Pilot Plants In Taiwan. J Environ Prot Ecol, 18 (3), 899-912 (2017). 15. Yu, W. L., and Guo, S. J.: Sustainability and Integration of Design and Construction Technology for Biological Agents Pilot Plant. In Proc. of the 23th KKCNN Symposium on Civil Engineering, Taipei, Taiwan, 473-476 (2010). 16. Zaki, N.: Biosafety and Biosecurity Measures: Management of Biosafety Level 3 Facilities. Int J Antimicrob Ag, 36, S70-S74 (2010). 17. Public Health Agency of Canada: The Laboratory Biosafety Guidelines. 3rd ed. Canada, 2004. 18. U.S. Department of Health and Human Services: Biosafety in Microbiological and Biomedical Laboratories (BMBL). 5th ed. HHS Publication No (CDC) 21-1112. Washington, DC, 2009. 19. World Health Organization (WHO): Laboratory Biosafety Manual. 3rd ed. Geneva, 2004. 20. 王世晞,製藥產業之演進、現況、與趨勢,國立臺灣大學商學研究所碩士論文,2003。 21. 王輔仁、黃靖雄、黃建民,生物安全實驗室供風配置之模擬分析,2013綠色科技工程與應用研討會(GTEA),261-266頁,2013。 22. 洪至讀,各類型生物實驗室之設計探討,中華顧問工程司建築部,2005。 23. 段雷,醫院手術室現有缺失及改善設略之研究,中華大學營建管理研究所碩士論文,2003。 24. 陳旻彬,生物科技廠建築規劃之基礎研究(以生物製劑藥廠潔淨空間為例),逢甲大學建築研究所在職專班碩士論文,2003。 25. 陳光華,生物安全等級三實驗室規劃重點之研究,中華大學營建管理研究所碩士論文,2004。 26. 郭斯傑、喻文莉,生物製劑先導工廠之生物安全防護機制探討,第19屆營建工程與管理學術研討會,2015。 27. 許世昌,生物科技衛生醫療實驗室之實驗動物設施硬體設施之研究,中華大學營建管理研究所碩士論文,2005。 28. 張靜文、于台珊,生物安全櫃種類、選用依據及操作安全介紹,勞工安全衛生研究所衛生組,2003。 29. 張陸滿,奈米時代高科技廠房設施工程,土木水利第35卷第1期,2008。 30. 喻文莉,生物製劑先導工廠建築規劃之研究,臺灣大學土木工程學研究所碩士論文,2006。 31. 喻文莉、戴期甦、郭斯傑,生物製劑先導工廠建築規劃之研究,中華民國建築學會第18屆第1次建築研究成果發表會,2006。 32. 喻文莉、郭斯傑,生物製劑先導工廠製程空間建築規劃之研究,建築學報76期增刊(技術專刊),23-42頁,2011。 33. 葉宏一,生技新藥審查法規與未來趨勢,行政院衛生署藥政處,2001。 34. 鄧明裕,GMP藥廠設施佈置規劃的探討--以E公司為研究對象,國立中央大學工業管理研究所在職專班碩士論文,2004。 35. 鄭詠仁,生物安全櫃操作安全技術手冊,行政院勞委會勞工安全衛生研究所,2004。 36. 簡文浩,潔淨對生技廠的影響,榮工亞翔2017秋季刊。 37. 蘇勳璧、蘇治原,實驗室生物安全規範,疾管局研究檢驗中心,疫情報導268期,2005。 38. cGMP藥廠空調系統確效作業技術交流討論會,經濟部工業局,1999。 39. cGMP無菌作業區清淨度分級及環境監控作業研討說明會,行政院衛生署,2003。 40. 生物安全第三等級實驗室安全規範(第2.0版),行政院衛生署疾管局,2011。 41. 生物安全第一等級至第三等級實驗室安全規範,第1.0版,行政院衛生署疾管局,2013。 42. 生物安全風險 -實驗室生物保全指引,行政院衛生署疾病管制局編譯,2010。 43. 基因重組實驗守則,行政院國家科學委員會,2004。 44. 清潔確效要點,財團法人中華無菌製劑協會。 45. 微生物和生物醫學實驗室生物安全通用準則,中國大陸,2002。 46. 製藥工業cGMP技術人才培訓計畫—製程相關確效作業,經濟部工業局,2002。 47. 實驗室生物安全手冊,世界衛生組織,中文版-疾管署編譯,2005。 48. 藥事法,行政院衛生福利部,2017。 49. 藥物製造工廠設廠標準,行政院衛生福利部,2013。 50. 藥物優良製造準則,行政院衛生署,2013。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20167 | - |
dc.description.abstract | 生技新藥產業是知識密集的產業,重視創新與發明,研發期程往往需達5-10年以上的時間,其間所需資本與遭遇風險較高,但成功後報酬率大,產品生命週期亦長。生技新藥產業發展模式不同於代工製造為主的產業,涉及知識研發、執行法規、支援設施及基礎環境等。生物科技產業發展逐漸重要的同時,將使得「生技產業類建築」成為一高度專業知識的建築領域,尤其生物科技發展對製程環境之空間配置亦產生極大影響,無論在法令規範、硬體設施、人員施作經驗或是相關資訊上,該類建築的規劃設計、空間配置、確效管理及查廠等均是值得國內建築業發展的領域;此新的衝擊,將可使台灣的產業實力從加工製造業向上提升到研發產業。
建造「生物製劑先導工廠」,必須符合國內外相關cGMP及生物安全第三等級實驗室相關法規規定,且須能通過確效及查廠。基於上述法令條款要求嚴謹及相關資料短缺,使成為本文研究探討之目的。 「生物製劑先導工廠」於新藥研發時,對產品品質要求嚴謹、製程過程的環境要求嚴格,製程空間需求皆須為無菌潔淨環境。國內對生技製程BSL3實驗空間的研究資料不足,案例亦過於稀少,使得國內建築規劃設計者對實驗室空間配置所需相關知識相當模糊,為因應下一波生物科技產業革命,對生技建築先導工廠空間規劃之研究更刻不容緩。本研究主要探討製程空間於規劃設計時的主要需求項目,並以不同實驗空間的製程流程,反映至空間動線,成為規劃設計時的優先考量項目,設計者可透過本研究建立之檢核要項掌握生物製劑製程空間明確需求,建立正確的設計程序,並提供設計者作為同類型建築空間設計之參考依據。 | zh_TW |
dc.description.abstract | The biopharmaceutical industry is a knowledge-intensive industry that values innovation and invention. Although capital costs and risks are high during the research and development stage, which can last from five to ten years, successful products offer high returns and their life cycles are long. The development model for the biopharmaceutical industry differs from that of the contract manufacturing industry. It involves researching and developing new knowledge, adhering to laws and regulations, establishing support facilities, and creating the underlying environment. As the biotechnology industry becomes increasingly valuable, biotechnology construction has become a highly specialized subfield of construction. In particular, advancements in biotechnology substantially impacted the configuration of space in a manufacturing environment. Areas worthy of further advancement in Taiwan’s construction industry include planning and design, space configuration, validation management, and plant inspections associated with biotechnology construction; specifically, the results of developing these areas can contribute to relevant laws and regulations, equipment and facilities, personnel experience. The impact of this new industry can upgrade Taiwan’s contract manufacturing industry to one with research and development capabilities.
The construction of a biologics pilot plant must comply with both the domestic and international Current Good Manufacturing Practice regulations and Safety Guidelines for Biosafety Level 3 Laboratory. A pilot plant must also be validated and properly inspected. The aforementioned laws and regulations involve stringent requirements but information about these laws and regulations is lacking. Therefore, the objective of the present study was to examine these laws and regulations. The development of a new drug at a biologics pilot plant involves rigorous requirements for product quality and the environment of biologics production; a production space must be a sterile cleanroom. In Taiwan, research data regarding biosafety level 3 laboratories are inadequate and examples of these laboratories are sparse, causing domestic architects and building planners to have limited knowledge about laboratory space configurations. To face the next wave of revolution in biotechnology industry, there is a pressing need for research into the space planning of biotechnology pilot plants. In this study, we identified the key requirements for planning and designing a production space and used production processes required in various laboratory spaces to identify the optimal flows within the space of the laboratory. These requirements can be regarded as the priority requirements for planning and design a laboratory space. By utilizing the key requirements identified by this study, designers can gain a thorough understanding of the requirements for an adequate biologics production space and establish an appropriate set of procedures for designing such spaces. The results of the study can serve as a reference for the design of similar spaces. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:41:21Z (GMT). No. of bitstreams: 1 ntu-107-D98521025-1.pdf: 7814385 bytes, checksum: 7f0dc27b130d89678fd13c4e41bc98f8 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書......I
致謝......II 摘要......II Abstract......IV Figures......X Tables......XIV I. Introduction......1 1.1 Research Motivation......1 1.2 Research Objectives......3 1.3 Scope of the Study......4 1.4 Research Methods......5 1.5 Research Process......7 II. Literature Review......8 2.1 Biological Safety Level, BSL......8 2.1.1 Biosafety Definition and Classification......8 2.1.2 Types of Biological Laboratories......13 2.1.3 Special Laboratory Equipment: BSCs......18 2.2 Biologics Plants......24 2.2.1 Definition of Biopharmaceuticals......24 2.2.2 Types of Biologics......25 2.2.3 Principles of the Biologics Production Process......26 2.2.4 Definition of a Biologics Pilot Plant......29 2.3 Cleanrooms......31 2.3.1 Cleanroom Definition and Classification......31 2.3.2 HVAC Characteristics of Biomedical Cleanrooms......36 III. Compilation and Analysis of Relevant Laws and Regulations and Expert Interviews......41 3.1 Compilation and Analysis of Relevant Laws and Regulations......41 3.1.1 Key Regulations Regarding Biosafety Zoning......42 3.1.2 Key Regulations Regarding the Cleanliness zoning......44 3.1.3 Key Regulations Regarding Personnel Flow......47 3.1.4 Key Regulations Regarding Equipment Flow......49 3.1.5 Key Regulations Regarding Preparation Flow......51 3.1.6 Key Regulations Regarding Waste Flow......52 3.1.7 Key Regulations Regarding Airflow differential......53 3.2 Expert Interviews......58 3.2.1 Objectives of Expert Interviews......58 3.2.2 Expert Interviewees......58 3.2.3 Expert Interviews: Composing Questions......59 3.2.4 Expert Interviews: Devising Solutions......60 IV. Validation and Deduction – Case Studies......70 4.1 Background Description of the Case Studies......71 4.1.1 Summary of Plant A......71 4.1.2 Summary of Plant B......73 4.2 Biosafety zoning......75 4.2.1 Description of Biosafety zoning......75 4.2.2 Analysis of Biosafety zoning in the Case Studies......76 4.3 Cleanliness zoning......78 4.3.1 Description of Cleanliness zoning......78 4.3.2 Analysis of Cleanliness zoning in the Case Studies......79 4.4 Personnel Flow......81 4.4.1 Description of Personnel Flow......81 4.4.2 Analysis of Personnel Flow in the Case Studies......82 4.5 Equipment Flow......83 4.5.1 Description of Equipment Flow......83 4.5.2 Analysis of Equipment Flow in the Case Studies......84 4.6 Preparation Flow......86 4.6.1 Description of Preparation Flow......86 4.6.2 Analysis of Preparation Flow in the Case Studies......87 4.7 Waste Flow......88 4.7.1 Description of Waste Flow......88 4.7.2 Analysis of Waste Flow in the Case Studies......89 4.8 Airflow differential......91 4.8.1 Description of Airflow differential......91 4.8.2 Analysis of Airflow differential in the Case Studies......92 4.9 Floor Plan Review and Suggestions for Improvement......94 4.9.1 Suggestions for Improvement in Plant A......94 4.9.2 Suggestions for Improvement in Plant B......104 4.10 Summary......114 4.10.1 Fundamental Space Requirements......117 4.10.2 Necessary and Required Facilities......119 V. Conclusion and Suggestions......121 5.1 Conclusion......121 5.2 Suggestions......122 5.3 Future Research......123 References......124 | |
dc.language.iso | en | |
dc.title | 生物製劑先導工廠-製程空間生物安全防護要項之研究 | zh_TW |
dc.title | Biologics Pilot Plant -Architecture of Biosafety and Biosecurity Design in Process Space | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 曾惠斌(Hui-Ping Tserng),張陸滿(Luh-Maan Chang),謝定亞(Ting-Ya Hsieh),鄭明淵(Min-Yuan Cheng) | |
dc.subject.keyword | 生物製劑先導工廠,BSL3實驗室,生物安全防護,交叉汙染,清淨度區域,氣流壓差, | zh_TW |
dc.subject.keyword | biologics pilot plant,biosafety level 3 laboratory,biosafety and biosecurity,cross contamination,clean zone,airflow differential, | en |
dc.relation.page | 127 | |
dc.identifier.doi | 10.6342/NTU201800136 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-02-12 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 土木工程學研究所 | zh_TW |
顯示於系所單位: | 土木工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 7.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。